Shannon F. Rudy

Shannon F. Rudy

Auto-generated profile, based on publicly available information

Shannon F. Rudy

Stanford University School of Medicine

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Facial Plastic Surgery Clinics of North America
Verified
Journal Article
Closed access
SMSam P. Most
Sam P. Most
SRShannon F. Rudy
Shannon F. Rudy

7 April 2017 in Facial Plastic Surgery
Verified
Journal Article
Closed access
PDF file
SRShannon Rudy
Shannon Rudy
SMSami P. Moubayed
Sami P. Moubayed
SMSam P. Most
Sam P. Most
The nasal midvault is an important consideration in rhinoplasty. This region is defined by the attachment of the upper lateral cartilages (ULCs) to the nasal bones superiorly and the cartilaginous septum medially. Inadequate management of the nasal midvault can have negative functional and aesthetic ramifications. Indications for midvault reconstruction in primary rhinoplasty include a narrow midvault, dorsal hump resection, a deviated midvault, and an asymmetric midvault, with an additional relative indication of zone 1 lateral wall insufficiency (LWI), defined as dynamic collapse of a weakened lateral nasal wall at the level of the ULC. Numerous techniques for midvault reconstruction have been described, dating back to Sheen's description of the spreader graft in the 1980s, which remains the gold standard for repair. Herein, the various indications for midvault reconstruction are described, along with a discussion of the most commonly used techniques for successful reconstruction.

4 September 2017 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
SRShannon F. Rudy
Shannon F. Rudy
CJCaroline C. Jeffery
Caroline C. Jeffery
EDEdward Damrose
Edward Damrose

28 August 2019 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
PDF file
TOTyler Stephen Okland
Tyler Stephen Okland
CKCherian Kandathil
Cherian Kandathil
ASAkshay Sanan
Akshay Sanan
SRShannon Rudy
Shannon Rudy
SMSam P. Most
Sam P. Most

1 December 2018 in JAMA Facial Plastic Surgery
Verified
Journal Article
Open access
PDF file
SRShannon F. Rudy
Shannon F. Rudy
KLKevin Li
Kevin Li
SMSami P. Moubayed
Sami P. Moubayed
SMSam P. Most
Sam P. Most
Importance: Although malignancy is an established risk factor for venous thromboembolism (VTE), the risk of VTE specifically in patients with keratinocyte carcinoma (KC) has not been previously studied. Objective: To determine the risk of VTE in patients with KC compared with patients not diagnosed with cancer and with patients diagnosed with common malignant neoplasms associated with VTE. Design, Setting, and Participants: Population-based retrospective analysis of patient insurance claims made between January 1, 2007, and December 31, 2014, from the Truven MarketScan Commercial and Medicare Supplemental Databases. Patients treated across the United States were divided into 3 cohorts: patients with KC, patients with pancreatic cancer or acute myelogenous leukemia who are thus at high risk for VTE, and patients without a history of common malignant neoplasms. Patients were excluded from the KC cohort if they had a history of another type of cancer. Data were analyzed between April 1, 2017, and January 15, 2018. Main Outcomes and Measures: Diagnosis of VTE within 1 year following the index date (for the KC and high-risk cohorts, the date of the initial diagnosis of cancer; for the control cohort, the date following 365 days of continuous insurance enrollment). Logistic regression was used to assess the risk of VTE in the KC cohort compared with the high-risk and control cohorts before and after matching across patient characteristics and known risk factors for VTE. Results: Of 5 753 613 potentially eligible patients, the final sample consisted of 740 246 patients (12.8%) across 3 cohorts. Of the 740 246 study participants, 417 839 were in the KC cohort (223 986 [53.6%] men, mean [SD] age, 64.2 [13.6] years); 314 736 were in the control cohort (135 203 [43.0%] men, 42.9 [15.2] years); and 7671 were in the high-risk cohort (3502 [45.7%] men, 59.4 [14.4] years) The risk of VTE in the KC cohort was lower compared with the high-risk cohort in univariable analysis (odds ratio [OR], 0.22; 95% CI, 0.20-0.23; P < .001), multivariable analysis (OR, 0.29; 95% CI, 0.26-0.32; P < .001), and after matching across patient characteristics and known risk factors (OR, 0.52; 95% CI, 0.35-0.78; P = .001). The risk of VTE in the KC cohort was higher in the univariable analysis (OR, 2.31; 95% CI, 2.23-2.41; P < .001), lower in the multivariable analysis (OR, 0.85; 95% CI, 0.80-0.90; P < .001), and not different after matching of patient characteristics and risk factors (OR, 0.95; 95% CI, 0.89-1.01; P = .08) than that of the control cohort. Conclusions and Relevance: The results of this study provided no evidence supporting the increased risk of VTE in the KC cohort compared with the control cohort. Given the inherent risks of chemoprophylaxis, the need for prophylactic anticoagulation in patients with KC who are scheduled for surgery should be carefully considered. Level of Evidence: NA .

28 July 2017 in Facial Plastic Surgery
Verified
Journal Article
Closed access
PDF file
SMSami P. Moubayed
Sami P. Moubayed
SMSam P. Most
Sam P. Most
SRShannon Rudy
Shannon Rudy
Anterior septal reconstruction (ASR) is a form of extracorporeal septoplasty used to treat anterocaudal septal deviation. Some patients also suffer from lateral wall insufficiency (LWI), where the lateral nasal wall collapses on inspiration. Specific therapies are used to treat LWI, but the isolated effect of ASR on LWI has not previously been studied. We hypothesized that patients undergoing ASR would experience improvement in LWI severity given the decrease in nasal resistance.